May 19, 2010 Researchers from the University of Helsinki, and Oncos Therapeutics, a biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research. The therapy program is based on scientific research at the University of Helsinki and serves as the foundation for ongoing clinical development.
The results demonstrate an anti-tumor immunity of oncolytic viruses -- published for the first time in humans -- and indicate the strong efficacy of the next generation viruses against solid tumor cancers. As of today, 200 patients have been treated with oncolytic virus therapy in the company's Advanced Therapy Access Program.
"This is the first time it has been shown in humans that oncolytic viruses can be used for the induction of anti-tumor immunity. The GMCSF -armed oncolytic adenovirus can mediate anti-tumor immunologic responses by recruiting natural killer cells and by the induction of tumor-specific cytotoxic T-cells," explains research professor Akseli Hemminki, the CSO and co-founder of Oncos.
"Anti-tumor immunity plays a major role in the strong efficacy results. We are starting clinical trials with CGTG-102, which is further improved compared of the virus described in this publication," comments Pekka Simula, the CEO and co-founder of Oncos.
The Cancer Research article reports strong safety and efficacy results in patients with advanced cancer progressing after available chemotherapy options. Out of the 15 radiologically evaluable patients 2 had complete responses (13%), 5 patients had stable disease (33 %) and 1 had a partial response (6 %). Therefore, the clinical benefit rate was 47% according to the RECIST criteria. Responses were frequently seen in both injected and non-injected tumors. The safety profile was favorable with no grade 4-5 side effects realized.
"It has been impressive to see how powerful and consistent the oncolytic adenovirus platform is for directing the body's own immune system against tumor cells" says Dr. Vincenzo Cerullo, the scientist who led the project at the University of Helsinki Cancer Gene Therapy Group (CGTG).
Other social bookmarking and sharing tools:
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
- Vincenzo Cerullo, Sari Pesonen, Iulia Diaconu, Sophie Escutenaire, Petteri T. Arstila, Matteo Ugolini, Petri Nokisalmi, Mari Raki, Leena Laasonen, Merja Särkioja, Maria Rajecki, Lotta Kangasniemi, Kilian Guse, Andreas Helminen, Laura Ahtiainen, Ari Ristimäki, Anne Räisänen-Sokolowski, Elina Haavisto, Minna Oksanen, Eerika Karli, Aila Karioja-Kallio, Sirkka-Liisa Holm, Mauri Kouri, Timo Joensuu, Anna Kanerva, and Akseli Hemminki. Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients. Cancer Research, 2010; DOI: 10.1158/0008-5472.CAN-09-3567
Note: If no author is given, the source is cited instead.